Aligos Therapeutics

DelveInsight's report on Nonalcoholic Steatohepatitis (NASH) provides insights into historical and forecasted epidemiology, market trends, current treatment practices, emerging drugs, and market size from 2019 to 2032 in the United States, EU5, and Japan. Key companies and therapies in the NASH market are highlighted, including recent developments like Aligos Therapeutics' Phase 1 data presentation.

Ipsen presents data at AASLD 2024 showing sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS treated with Bylvay® (odevixibat). Open-label extension studies PEDFIC 2 and ASSERT-EXT demonstrate long-term efficacy and safety, with improvements in height, weight, and sleep measures. Ipsen remains committed to advancing treatments for rare cholestatic liver diseases.

Ipsen presents data on Bylvay's long-term efficacy and safety in PFIC and ALGS at AASLD 2024, showing sustained improvements in pruritus, serum bile acid levels, height, weight, and sleep measures.

Bylvay® (odevixibat) demonstrates sustained improvement in severe itch and serum bile acid levels in PFIC and ALGS patients, with data from PEDFIC 2 and ASSERT-EXT studies presented at AASLD 2024.

Aligos Therapeutics announces FDA clearance for Phase 1 DDI study of ALG-000184, a CAM-E for CHB, with Phase 2 filing planned for Q1 2025.

Ipsen reports YTD 2024 total sales growth of 9.2% at CER, driven by Dysport, Cabometyx, and Bylvay. Regulatory approvals for Iqirvo and Kayfanda, and increased 2024 guidance: total-sales growth >8.0% at CER, core operating margin >31.0%.

Aligos Therapeutics reported positive Phase IIa HERALD trial results for ALG-055009, a thyroid hormone receptor beta agonist, in treating metabolic-dysfunction-associated steatohepatitis (MASH). The study, involving 102 subjects with stage I-III liver fibrosis, showed significant reductions in liver fat content and favorable tolerability, with no serious adverse events.